Log in to search using one of your social media accounts:

 

Tocilizumab Benefits Persist in SSc (CME/CE)
(MedPage Today) -- Clinically meaningful results, but not statistically significant (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 25, 2017 Category: Primary Care Source Type: news

Godly gift for arthritis pain
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year. In 2015, the FDA asked drug makers to strengthen their warning labels. Since then, most have listed their dangerous side effects on the bottle. But one manufacturer thought they didn’t have to warn people about their dangerous drug. They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1 The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche....
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

RA Outcomes with Tocilizumab Surpass Those of Adalimumab, Methotrexate (CME/CE)
(MedPage Today) -- Benefits reflected in both physical and mental scores (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - September 25, 2017 Category: Rheumatology Source Type: news

European Commission approves Roche ’s tocilizumab to treat giant cell arteritis
Roche ’s Actemra / RoActemra (tocilizumab) has received approval from the European Commission (EC) to treat giant cell arteritis (GCA). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 24, 2017 Category: Pharmaceuticals Source Type: news

Roche receives EU approval for Gazyvaro, European approval for Actemra
ZURICH (Reuters) - Roche said it has received European approval for its Actemra medication in giant cell arteritis (GCA), the Swiss drugmaker said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - September 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Roche receives European approval for Actemra /RoActemra in giant cell arteritis
Roche announced today that the European Commission (EC) has approved Actemra ®/RoActemra® (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition. Actemra/RoActemra is the first therapy approved for the treatment of GCA in Europe. (Source: Roche Media News)
Source: Roche Media News - September 22, 2017 Category: Pharmaceuticals Source Type: news

Roche receives European approval for Actemra /RoActemra in giant cell arteritis
Roche announced today that the European Commission (EC) has approved Actemra ®/RoActemra® (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition. Actemra/RoActemra is the first therapy approved for the treatment of GCA in Europe. (Source: Roche Investor Update)
Source: Roche Investor Update - September 22, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Genentech ’s Actemra (tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
South San Francisco, CA -- August 30, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra ® (tocilizumab) intravenous injection for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 31, 2017 Category: Drugs & Pharmacology Source Type: news

FDA approves Roche ’s Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome
Roche announced today that the US Food and Drug Administration (FDA) has approved Actemra/RoActemra ® (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in patients two years of age and older. (Source: Roche Media News)
Source: Roche Media News - August 30, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome
Roche announced today that the US Food and Drug Administration (FDA) has approved Actemra/RoActemra ® (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in patients two years of age and older. (Source: Roche Investor Update)
Source: Roche Investor Update - August 30, 2017 Category: Pharmaceuticals Source Type: news

Tocilizumab Boosts Hemoglobin, Hematocrit in RA (CME/CE)
(MedPage Today) -- Significant increases for anemic RA patients at 6 and 24 months (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - August 12, 2017 Category: Geriatrics Source Type: news

Tocilizumab May Be Option in Giant Cell Arteritis (CME/CE)
(MedPage Today) -- Biologic agent with steroid taper performed better than steroids alone (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - August 11, 2017 Category: Consumer Health News Source Type: news

Genentech ’s Actemra meets primary and secondary endpoints in Phase III trial for GCA
Genentech has reported positive results from the Phase III GiACTA clinical trial of Actemra (tocilizumab) to treat adults with giant cell arteritis (GCA). (Source: Drug Development Technology)
Source: Drug Development Technology - July 27, 2017 Category: Pharmaceuticals Source Type: news

Tocilizumab With Steroid Taper Superior in GCA Tocilizumab With Steroid Taper Superior in GCA
Tocilizumab plus a 26-week prednisone taper was superior to either a short or long course of tapered prednisone treatment plus placebo in patients with giant cell arteritis, a study has found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 27, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Drug Beats Steroids for Controlling Blood Vessel Inflammation in Study
With tocilizumab's approval, there's an alternative treatment for giant cell arteritis Source: HealthDay Related MedlinePlus Pages: Giant Cell Arteritis, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - July 27, 2017 Category: Consumer Health News Source Type: news

Your NEJM Group Today: Rejecting Science, Harming Women / Tocilizumab for Giant-Cell Arteritis / NJ Primary Care Opportunities (FREE)
By the Editors Take a look at today's offering from NEJM Group:NEJM Audio Interview: Rejecting Science, Harming … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 27, 2017 Category: Primary Care Source Type: news

Tocilizumab Beats Steroids for Controlling Blood Vessel Inflammation in Study
WEDNESDAY, July 26, 2017 -- The drug tocilizumab performs better than steroids in treating the most common form of blood vessel inflammation known as giant cell arteritis, a new study has shown. The phase 3 clinical trial of 251 patients confirmed... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 26, 2017 Category: General Medicine Source Type: news

Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Actemra ®/RoActemra® (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition. (Source: Roche Media News)
Source: Roche Media News - July 21, 2017 Category: Pharmaceuticals Source Type: news

Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Actemra ®/RoActemra® (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition. (Source: Roche Investor Update)
Source: Roche Investor Update - July 21, 2017 Category: Pharmaceuticals Source Type: news

IL-6 vs TNF: Tocilizumab Wins (CME/CE)
(MedPage Today) -- In an observational study, efficacy and drug survival greater with tocilizumab (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 21, 2017 Category: Geriatrics Source Type: news

Tocilizumab Triumphs in Methotrexate Combo for RA Tocilizumab Triumphs in Methotrexate Combo for RA
It is not always clear which biologic to add to methotrexate for rheumatoid arthritis, but a new comparison between tocilizumab and a number of TNF inhibitors has some suggestions.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Monthly News Roundup - May 2017
Actemra: First Drug Approved to Treat Giant Cell Arteritis Actemra (tocilizumab) from Hoffman La Roche has gained a new indication as the first drug approved to treat adults with giant cell arteritis, a specific type of vasculitis. Vasculitis is... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 30, 2017 Category: Pharmaceuticals Source Type: news

Actemra Approved for Certain Blood Vessel Inflammation
Title: Actemra Approved for Certain Blood Vessel InflammationCategory: Health NewsCreated: 5/22/2017 12:00:00 AMLast Editorial Review: 5/23/2017 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - May 23, 2017 Category: Rheumatology Source Type: news

FDA approves Roche ’s Actemra/RoActemra (tocilizumab) for giant cell arteritis
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra ®/RoActemra® (tocilizumab) ) subcutaneous injection for the treatment of GCA, a chronic and severe autoimmune condition. (Source: Roche Media News)
Source: Roche Media News - May 23, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Actemra/RoActemra (tocilizumab) for giant cell arteritis
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra ®/RoActemra® (tocilizumab) ) subcutaneous injection for the treatment of GCA, a chronic and severe autoimmune condition. (Source: Roche Investor Update)
Source: Roche Investor Update - May 23, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves First Treatment Specifically for Giant Cell Arteritis (FREE)
By the Editors Subcutaneous tocilizumab (Actemra) is now approved for adults with giant cell arteritis, the FDA announced … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 22, 2017 Category: Primary Care Source Type: news

FDA Approves Tocilizumab (Actemra) for Giant Cell Arteritis FDA Approves Tocilizumab (Actemra) for Giant Cell Arteritis
The FDA has expanded the approved use of subcutaneous tocilizumab (Actemra, Hoffman LaRoche) to include treatment of adults with giant cell arteritis.FDA Approvals (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - May 22, 2017 Category: Emergency Medicine Tags: Rheumatology News Alert Source Type: news

IL-6 Blocker OK'd for Vasculitis
(MedPage Today) -- FDA approved steroid-sparing tocilizumab for giant cell arteritis (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 22, 2017 Category: Primary Care Source Type: news

Actemra Approved for Certain Blood Vessel Inflammation
Drug will treat adults with a condition called vasculitis Source: HealthDay Related MedlinePlus Pages: Giant Cell Arteritis, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 22, 2017 Category: Consumer Health News Source Type: news

FDA approves first drug to specifically treat giant cell arteritis
The U.S. Food and Drug Administration today expanded the approved use of subcutaneous Actemra (tocilizumab) to treat adults with giant cell arteritis. This new indication provides the first FDA-approved therapy, specific to this type of vasculitis. (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 22, 2017 Category: American Health Source Type: news

Actemra Approved for Certain Blood Vessel Inflammation
MONDAY, May 22, 2017 -- The injected drug Actemra (tocilizumab) has been approved by the U.S. Food and Drug Administration to treat adults with giant cell arteritis, an inflammation of the blood vessels (vasculitis). In a media release Monday, the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 22, 2017 Category: General Medicine Source Type: news

FDA Approves Actemra (tocilizumab) Subcutaneous Injection for Giant Cell Arteritis
May 22, 2017 -- The U.S. Food and Drug Administration today expanded the approved use of subcutaneous Actemra (tocilizumab) to treat adults with giant cell arteritis. This new indication provides the first FDA-approved therapy, specific to this type... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 22, 2017 Category: Drugs & Pharmacology Source Type: news

tocilizumab, Actemra
Title: tocilizumab, ActemraCategory: MedicationsCreated: 9/13/2010 12:00:00 AMLast Editorial Review: 5/16/2017 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - May 16, 2017 Category: Rheumatology Source Type: news

US FDA accepts Genentech Actemra ’s sBLA for Giant Cell Arteritis
The US Food and Drug Administration (FDA) has accepted Genentech ’s supplemental biologics licence application (sBLA) for Actemra (tocilizumab) for the treatment of Giant Cell Arteritis (GCA). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 25, 2017 Category: Pharmaceuticals Source Type: news

FDA Grants Priority Review for Genentech’s Actemra(R) (Tocilizumab) Supplemental Biologics License Application for Giant Cell Arteritis, a Form of Vasculitis
SOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing Network)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Supplemental Biologics Lic... Biopharmaceuticals, FDA Genentech, Roche Group, Actemra, Tocilizumab, Giant Cell Arteritis, Vasculitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 24, 2017 Category: Pharmaceuticals Source Type: news

Roche says FDA grants priority review for Actemra
ZURICH (Reuters) - The U.S. Food and Drug Administration (FDA) has granted priority review designation of Roche's rheumatoid arthritis medication Actemra for giant cell arteritis (GCA), the Swiss drugmaker said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - January 24, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA grants priority review for Roche ’s Actemra/RoActemra (tocilizumab) supplemental biologics license application for giant cell arteritis, a form of vasculitis
Roche announced today that the U.S. Food and Drug Administration (FDA) has accepted the company ’s supplemental biologics license application (sBLA) for Actemra/RoActemra (tocilizumab) for the treatment of GCA, a chronic, potentially life-threatening autoimmune condition. (Source: Roche Investor Update)
Source: Roche Investor Update - January 24, 2017 Category: Pharmaceuticals Source Type: news

Tocilizumab in RA With Inadequate Response to Methotrexate Tocilizumab in RA With Inadequate Response to Methotrexate
Does the addition of or switch to tocilizumab provide any additional benefits for rheumatoid arthritis patients who do not sufficiently respond to methotrexate alone?Annals of the Rheumatic Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 7, 2016 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Slight, Nonsignificant CV Risk with Actemra vs Enbrel
(MedPage Today) -- Few events seen with either agent (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - November 29, 2016 Category: Journals (General) Source Type: news

Slight, Nonsignificant CV Risk with Actemra vs Embrel
(MedPage Today) -- Few events seen with either agent (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 28, 2016 Category: Cardiology Source Type: news

Study Tests Tocilizumab for Systemic Juvenile Idiopathic Arthritis in Clinical Setting
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - November 19, 2016 Category: Orthopaedics Tags: Perspective Source Type: news

Actemra Carries Slight Increase in Heart Risk vs. Enbrel
(MedPage Today) -- But efficacy, too, must be weighed in treatment decisions (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 17, 2016 Category: Cardiology Source Type: news

ACR: Actemra Found Steroid-Sparing in GCA
(MedPage Today) -- The era of unending steroid treatment is over (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - November 15, 2016 Category: Journals (General) Source Type: news

GCA trial's new data indicates 56% of people treated with RoActemra achieved steroid-free disease remission
New data from giant-cell arteritis (GCA) trial indicates that 56% of people treated with RoActemra (tocilizumab) achieved steroid-free disease remission at one year, compared with only 14% given the present standard of care with steroids alone. (Source: Drug Development Technology)
Source: Drug Development Technology - November 14, 2016 Category: Pharmaceuticals Source Type: news

Roche announces positive results for Actemra in phase III study
VIENNA (Reuters) - Swiss drugmaker Roche said on Sunday its rheumatoid arthritis medication Actemra for giant cell arteritis showed to be superior to steroids alone in maintaining steroid-free remission in a Phase III study. (Source: Reuters: Health)
Source: Reuters: Health - November 13, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Phase III GiACTA study shows Roche ’s Actemra/RoActemra is superior to steroids alone in maintaining steroid-free remission for people with giant cell arteritis
Roche today announced positive results from the phase III GiACTA study, which evaluated Actemra ®/RoActemra® (tocilizumab) in people with giant cell arteritis (GCA). (Source: Roche Media News)
Source: Roche Media News - November 12, 2016 Category: Pharmaceuticals Source Type: news

Phase III GiACTA study shows Roche ’s Actemra/RoActemra is superior to steroids alone in maintaining steroid-free remission for people with giant cell arteritis
Roche today announced positive results from the phase III GiACTA study, which evaluated Actemra ®/RoActemra® (tocilizumab) in people with giant cell arteritis (GCA). (Source: Roche Investor Update)
Source: Roche Investor Update - November 12, 2016 Category: Pharmaceuticals Source Type: news

Actemra (Tocilizumab Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 11, 2016 Category: Drugs & Pharmacology Source Type: news

Roche to present new data on medicines for autoimmune diseases and severe inflammatory disorders at the 2016 ACR/ARHP Annual Meeting
Roche today announced that new data from Actemra ®/RoActemra® and Rituxan®/MabThera® will be presented during the 2016 American College of Rheumatology (ACR) and Association for Rheumatology Health Professionals (ARHP) Annual Meeting from 11-16 November in Washington, D.C, US. (Source: Roche Media News)
Source: Roche Media News - November 2, 2016 Category: Pharmaceuticals Source Type: news

Roche to present new data on medicines for autoimmune diseases and severe inflammatory disorders at the 2016 ACR/ARHP Annual Meeting
Roche today announced that new data from Actemra ®/RoActemra® and Rituxan®/MabThera® will be presented during the 2016 American College of Rheumatology (ACR) and Association for Rheumatology Health Professionals (ARHP) Annual Meeting from 11-16 November in Washington, D.C, US. (Source: Roche Investor Update)
Source: Roche Investor Update - November 2, 2016 Category: Pharmaceuticals Source Type: news